99%+ HPLC purityThird-party testedCOA with every lot Mass-spec confirmed identityISO/IEC 17025 labsEndotoxin screenedInsured priority shipping · tracked
≥99% PuritySelank / Semax vialUSA Lab VerifiedISO/IEC 17025

Selank / Semax

Two-peptide blend · lyophilized

$55.00Out of stock
USA Lab VerifiedISO/IEC 17025:2017View COA
Size

Get an email when Selank / Semax is back

Leave your email and we will send one note the moment it is back in stock.

One email when it restocks, plus occasional Eon updates. Unsubscribe anytime.

Free Shipping on orders over $200

Secure Checkout
Third-Party Tested
Money-Back Guarantee
PASSEDSterility & Endotoxins
PASSEDNet Content & Purity
Authenticity

Every vial is QR-authenticated

Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.

Researchers also added

More to explore.

Research use only.

The Eon standard

High Purity Guarantee

Your results are only as good as your compound.

Every lot of Selank / Semax is tested by an independent ISO/IEC 17025-accredited lab in the USA. 99%+ purity isn't a target here. It's the requirement.

Don't take our word for it: test any vial at an accredited lab of your choice. If HPLC purity comes back under 99%, we refund your order and pay for the test.

Size
5mg / 5mg
Purity
99%+ by HPLC · guaranteed
Identity
Confirmed by mass spec
Lab
ISO/IEC 17025 · USA
View COA
About this compound

This is a blend. Selank and Semax are combined in a single vial in equal parts. Selank is a tuftsin-derived peptide studied for anxiolytic-like endpoints and GABAergic signalling; Semax is an ACTH(4-10) analog studied for BDNF expression and neuroprotection. Both originate from the same research lineage and are frequently studied together, though the combination is not characterised as a single formulation.

Two-peptide blend: Selank + Semax, equal parts

Form
Lyophilized powder blend
Purity
≥99% by HPLC
Vial size
5mg / 5mg · 10mg / 10mg
Class
Peptide blend
Read the full Selank / Semax research monograph
Research Snapshot

Selank / Semax research, by the numbers.

The numbers that define Selank / Semax and how it is being studied. For laboratory research use only.

  • 2

    Research Peptides

    Selank · Semax

  • 7

    Residues Each

    Both are heptapeptides

  • BDNF

    Semax Endpoint

    Neurotrophic factor expression

  • 4

    Research Areas

    • Anxiolytic models
    • Cognition
    • Neuroprotection
How It Works

How Selank / Semax works

The pathways Selank / Semax acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.

Signalling pathways studied in preclinical models · illustrative
Anxiolytic-Like Signalling
Selank

Selank is a synthetic analog of the immunomodulatory peptide tuftsin. GABAergic signalling and anxiolytic-like endpoints are the characterised readouts in rodent models, alongside effects on enkephalin degradation.

  • Tuftsin analog
  • GABAergic signalling
  • Anxiolytic-like endpoints
BDNF Expression & Neuroprotection
Semax

Semax is an ACTH(4-10) analog without corticotropic activity. Elevated BDNF and NGF expression is measured in rodent hippocampus, and neuroprotective endpoints are characterised in ischaemia models.

  • ACTH(4-10) analog
  • BDNF / NGF expression
  • Neuroprotection endpoints
Shared Research Lineage
Combined

Both peptides come from the same Russian research lineage and are frequently studied in parallel. The combination itself has not been characterised.

  • Same research lineage
  • Frequently studied in parallel
  • Interaction not characterised
Uses & Applications

What Selank / Semax is researched for

The main areas Selank / Semax is being studied for - and the study-reported figures behind them.

Neuroscience

Anxiolytic Models

Selank is characterised for anxiolytic-like endpoints in standard rodent behavioural models.

Neuroscience

Neurotrophic Expression

Semax is studied for BDNF and NGF expression in rodent hippocampus.

Neuroscience

Ischaemia Models

Neuroprotective endpoints for Semax are characterised in cerebral ischaemia research.

Methods

Parallel Protocols

One vial holds both peptides under matched handling for parallel work.

Study-reported magnitudes

Representative figures from published research. Bars fill as you scroll.

Semax BDNF ExpressionMeasured
Selank Anxiolytic-Like EndpointsMeasured
Neuroprotection (Ischaemia Models)Characterised
Blend Interaction DataNone

Figures are representative of published research findings and shown for reference.

Molecular Structure

The Selank / Semax molecule

An interactive 3D model rendered from the compound record - rotate and explore its structure.

Molecular model

Sequence length
blend
Physical form
Lyophilized powder blend
Documented purity
≥99% by HPLC
Compound Information

Full specification

ComponentsSelank + Semax
Selank SequenceThr-Lys-Pro-Arg-Pro-Gly-Pro (tuftsin analog)
Semax SequenceMet-Glu-His-Phe-Pro-Gly-Pro (ACTH 4-10 analog)
FormLyophilized powder blend
Purity≥99% by HPLC
AppearanceWhite to off-white powder
SolubilityWater-soluble
Storage-20°C, protected from light
ClassificationResearch use only
FAQ

Common questions about Selank / Semax

Both are heptapeptides from the same research lineage and are frequently studied in parallel, Selank for anxiolytic-like endpoints and Semax for neurotrophic expression. One vial holds both under matched handling.

No. Each peptide is characterised separately and no interaction data exists for the pair.

Two: 5 mg of each peptide, and 10 mg of each. The ratio is equal parts in both.

Each lot is analysed by reverse-phase HPLC and released at ≥99%, with a Certificate of Analysis.

Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.

Research Use Only.

Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.